140 related articles for article (PubMed ID: 26083214)
41. Smad7 Knockdown Restores Aryl Hydrocarbon Receptor-mediated Protective Signals in the Gut.
Monteleone I; Marafini I; Zorzi F; Di Fusco D; Dinallo V; Rizzo A; Sileri P; Sica G; Monteleone G
J Crohns Colitis; 2016 Jun; 10(6):670-7. PubMed ID: 26818761
[TBL] [Abstract][Full Text] [Related]
42. Letter: Effectiveness of split-dose certolizumab pegol for Crohn's disease.
Kane SV; Neis B; Becker BD; Bruining D; Faubion WA; Kisiel J; Loftus EV; Pardi D; Raffals L; Schroeder K; Tremaine WJ
Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1412. PubMed ID: 24206378
[No Abstract] [Full Text] [Related]
43. Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis.
Boirivant M; Pallone F; Di Giacinto C; Fina D; Monteleone I; Marinaro M; Caruso R; Colantoni A; Palmieri G; Sanchez M; Strober W; MacDonald TT; Monteleone G
Gastroenterology; 2006 Dec; 131(6):1786-98. PubMed ID: 17087939
[TBL] [Abstract][Full Text] [Related]
44. Adalimumab and Azathioprine Combination Therapy for Crohn's Disease: A Shining Diamond?
Fiorino G; Danese S
J Crohns Colitis; 2016 Nov; 10(11):1257-1258. PubMed ID: 27389085
[No Abstract] [Full Text] [Related]
45. Tremor as dose dependent side-effect of azathioprine in remission patient with ileal Crohn's disease.
Karaahmet F; Akinci H; Ayte R; Hamamci M; Coskun Y; Yuksel I
J Crohns Colitis; 2013 Oct; 7(9):e404. PubMed ID: 23623283
[No Abstract] [Full Text] [Related]
46. Smad7 Antisense Oligonucleotide in Crohn's Disease: A Re-Evaluation and Explanation for the Discordant Results of Clinical Trials.
Monteleone G; Stolfi C
Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678723
[TBL] [Abstract][Full Text] [Related]
47. Does preoperative immunosuppression influence unplanned hospital readmission after surgery in patients with Crohn's disease?
White EC; Melmed GY; Vasiliauskas E; Dubinsky M; Ippoliti A; McGovern D; Targan S; Fleshner P
Dis Colon Rectum; 2012 May; 55(5):563-8. PubMed ID: 22513435
[TBL] [Abstract][Full Text] [Related]
48. Oligonucleotide-Based Therapies for Inflammatory Bowel Disease.
Bevivino G; Sedda S; Marafini I; Monteleone G
BioDrugs; 2018 Aug; 32(4):331-338. PubMed ID: 29948918
[TBL] [Abstract][Full Text] [Related]
49. Histoplasma epiglottitis in a patient with Crohn's disease maintained on infliximab, prednisone, and azathioprine.
Abou Zahr A; Saad Aldin E; Yunyongying P
Int J Infect Dis; 2013 Aug; 17(8):e650-2. PubMed ID: 23769453
[TBL] [Abstract][Full Text] [Related]
50. Eruptive benign melanocytic naevi during immunosuppressive therapy in a Crohn's disease patient.
de Boer NK; Kuyvenhoven JP
Inflamm Bowel Dis; 2011 Jun; 17(6):E26. PubMed ID: 21287668
[No Abstract] [Full Text] [Related]
51. [Drug treatment of Crohn's disease].
van Deventer SJ; Tytgat GN
Ned Tijdschr Geneeskd; 1998 May; 142(21):1191-5. PubMed ID: 9627451
[TBL] [Abstract][Full Text] [Related]
52. Crohn's trial shows the pros of antisense.
Robertson D
Nat Biotechnol; 1997 Mar; 15(3):209. PubMed ID: 9062911
[No Abstract] [Full Text] [Related]
53. What is the optimal maintenance treatment for perianal Crohn's disease?
Schwartz DA
Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S269-70. PubMed ID: 18816761
[No Abstract] [Full Text] [Related]
54. Tacrolimus toxicity following topical treatment of perianal Crohn's disease: an admonitory anecdote.
Ali FR; Lyon CC
J Crohns Colitis; 2013 Dec; 7(12):e713. PubMed ID: 24076430
[No Abstract] [Full Text] [Related]
55. Methotrexate for maintenance of remission in Crohn's disease.
Patel V; Macdonald JK; McDonald JW; Chande N
Cochrane Database Syst Rev; 2009 Oct; (4):CD006884. PubMed ID: 19821390
[TBL] [Abstract][Full Text] [Related]
56. Drug-induced erythema nodosum after the administration of certolizumab in Crohn's disease.
Biedermann L; Kerl K; Rogler G; Hofbauer GF
Inflamm Bowel Dis; 2013 Jan; 19(1):E4-6. PubMed ID: 22127817
[No Abstract] [Full Text] [Related]
57. Initiating azathioprine for Crohn's disease.
Levesque BG; Loftus EV
Clin Gastroenterol Hepatol; 2012 May; 10(5):460-5. PubMed ID: 22330233
[TBL] [Abstract][Full Text] [Related]
58. Successful implementation of a nurse-led teaching programme to independently administer subcutaneous methotrexate in the community setting to children with Crohn's disease.
Garrick V; Atwal P; Barclay AR; McGrogan P; Russell RK
Aliment Pharmacol Ther; 2009 Jan; 29(1):90-6. PubMed ID: 18945263
[TBL] [Abstract][Full Text] [Related]
59. Kaposi's sarcoma developing in a HIV-negative Crohn's disease patient shortly after azathioprine and corticosteroid treatment.
Kilincalp S; Akıncı H; Hamamci M; Coşkun Y; Yüksel I
J Crohns Colitis; 2014 Jun; 8(6):558-9. PubMed ID: 24291020
[No Abstract] [Full Text] [Related]
60. A randomized controlled trial of two hepatitis A vaccine doses among adolescents with juvenile idiopathic arthritis and Crohn's disease on immunosuppressive therapy: a pilot study.
Githumbi R; Kuhn S; Osiowy C; Day J; deBruyn JCC; Fritzler MJ; Johnson NA; Vanderkooi O; Schmeling H
J Travel Med; 2024 Jun; 31(4):. PubMed ID: 38652172
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
